Assessment of Dual-Probe Her-2 Fluorescent in Situ Hybridization in Breast Cancer by the 2013 ASCO/CAP Guidelines Produces More Equivocal Results Than That by the 2007 ASCO/CAP Guidelines

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-016-3917-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

JAMA Oncology
Cancer ResearchOncology
2019English

Quantitative Assessments and Clinical Outcomes in HER2 Equivocal 2018 ASCO/CAP ISH Group 4 Breast Cancer

npj Breast Cancer
OncologyRadiologyNuclear MedicinePharmacologyImaging
2019English

HER2-ASCO-Guidelines

Der Pathologe
Forensic MedicinePathology
2010English

Breast Cancer News From ASCO 2013

Breast Care
SurgeryOncology
2013English

ASCO 2015: Highlights in Breast Cancer

Memo - Magazine of European Medical Oncology
OncologyHematology
2015English

Strong Correlation Between Results of Fluorescent in Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma

Modern Pathology
Forensic MedicinePathology
2000English

Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent in Situ Hybridization: The Importance of Probe Design

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma

Journal of Pathology and Translational Medicine
Forensic MedicinePathologyHistology
2016English

2007 EORTC-NCI-ASCO Annual Meeting. Molecular Markers in Cancer

ecancermedicalscience
Cancer ResearchOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy